Diaceutics PLCLSE: DXRX

Diaceutics: Director/PDMR Shareholding

· Issued by Diaceutics PLC via RNS

Summary by 6ix AI

On November 12, 2026, Diaceutics PLC Chair Peter Keeling and Delia Keeling, a person closely associated with him, each sold 1,750,000 ordinary shares; CEO Ryan Keeling sold 500,000 and Robyn Keeling, a person closely associated with him, sold 100,000; Chief Customer Officer Jordan Clark sold 250,000. All sold at 190 pence per share on AIM, a London Stock Exchange market.

Key details

  • After the sale, Peter and Delia Keeling's combined holding is 11,752,049 ordinary shares, approximately 13.78% of the issued share capital.
  • After the sale, Ryan and Robyn Keeling's combined holding is 2,390,643 ordinary shares, approximately 2.80% of the issued share capital.
  • After the sale, Jordan Clark holds 333,468 ordinary shares, approximately 0.39% of the issued share capital.
  • In major-holding notifications (TR-1 forms), Peter Keeling's total position, counting shares and employee share options, was 14.11% (12,034,517 voting rights), down from 18.21% in his previous notification; Ryan Keeling's was 4.72% (4,031,566 voting rights), down from 5.43%.

6ix AI wrote this summary from the release below and checked it against the release.

Diaceutics PLC
13 November 2026

Diaceutics PLC

PDMR/PCA Shareholdings & TR-1 Notifications

New York, Belfast and London, 13 November 2026 - Diaceutics PLC (AIM: DXRX) (“Diaceutics” or the “Company”), the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies, announces that it has been notified that on 12 November 2026:

  • Delia Keeling, a person closely associated with Peter Keeling, Chair of Diaceutics, sold 1,750,000 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of 190 pence per Ordinary Share.
  • Peter Keeling, Chair of Diaceutics, sold 1,750,000 Ordinary Shares at a price of 190 pence per Ordinary Share. As a result of the sale, Peter and Delia Keeling's combined shareholding in Diaceutics is 11,752,049 Ordinary Shares representing approximately 13.78% of the Company's issued share capital.
  • Robyn Keeling, a person closely associated with Ryan Keeling, Chief Executive Officer of Diaceutics, sold 100,000 Ordinary Shares at a price of 190 pence per Ordinary Share.
  • Ryan Keeling, Chief Executive Officer of Diaceutics, sold 500,000 Ordinary Shares at a price of 190 pence per Ordinary Share. As a result of the sale, Ryan and Robyn Keeling's combined shareholding in Diaceutics is 2,390,643 Ordinary Shares representing approximately 2.80% of the Company's issued share capital.
  • Jordan Clark, Chief Customer Officer of Diaceutics, sold 250,000 Ordinary Shares at a price of 190 pence per Ordinary Share. As a result of the sale, Jordan Clark’s shareholding in Diaceutics is 333,468 Ordinary Shares representing approximately 0.39% of the Company's issued share capital.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. The person responsible for making this announcement on behalf of the Company is Nick Roberts, Chief Financial Officer.

Enquiries:

Diaceutics PLC

Ryan Keeling, Chief Executive Officer

Tel: +44 (0)28 9040 6500

Nick Roberts, Chief Financial Officer

investorrelations@diaceutics.com

Canaccord Genuity Limited (Nomad & Broker)

Tel: +44 (0)20 7253 8000

Simon Bridges, Andrew Potts, Harry Rees

About Diaceutics

At Diaceutics, our mission is to redefine commercialization for diagnostic-driven therapies, so every eligible patient is found, diagnosed and receives the right therapy at the right time. Since 2005, we have combined diagnostic intelligence, expert insight and targeted engagement to help biopharma teams see where patients are being missed and close the gaps between testing, treatment decisions and therapy adoption. Today, we work with 21 of the top 30 pharma companies, and the therapies we support touch 1 in 10 American lives. We envision a future where precision is not the privilege of the few, but the standard for all.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Delia Keeling

2

Reason for notification

a.

Position/Status

PCA to Peter Keeling, Chair

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of £0.002 each

ISIN: GB00BJQTGV64

b.

Nature of the transaction

Sale

c.

Price(s) and volume(s)

Price(s)

Volume(s)

£1.90

1,750,000

d.

Date of the transaction

12 November 2026

e.

Place of the transaction

AIM Market of the London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Peter Keeling

2

Reason for notification

a.

Position/Status

Chair

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of £0.002 each

ISIN: GB00BJQTGV64

b.

Nature of the transaction

Sale

c.

Price(s) and volume(s)

Price(s)

Volume(s)

£1.90

1,750,000

d.

Date of the transaction

12 November 2026

e.

Place of the transaction

AIM Market of the London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Robyn Keeling

2

Reason for notification

a.

Position/Status

PCA to Ryan Keeling, Chief Executive Officer

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of £0.002 each

ISIN: GB00BJQTGV64

b.

Nature of the transaction

Sale

c.

Price(s) and volume(s)

Price(s)

Volume(s)

£1.90

100,000

d.

Date of the transaction

12 November 2026

e.

Place of the transaction

AIM Market of the London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Ryan Keeling

2

Reason for notification

a.

Position/Status

Chief Executive Officer

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of £0.002 each

ISIN: GB00BJQTGV64

b.

Nature of the transaction

Sale

c.

Price(s) and volume(s)

Price(s)

Volume(s)

£1.90

500,000

d.

Date of the transaction

12 November 2026

e.

Place of the transaction

AIM Market of the London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Jordan Clark

2

Reason for notification

a.

Position/Status

Chief Customer Officer

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of £0.002 each

ISIN: GB00BJQTGV64

b.

Nature of the transaction

Sale

c.

Price(s) and volume(s)

Price(s)

Volume(s)

£1.90

250,000

d.

Date of the transaction

12 November 2026

e.

Place of the transaction

AIM Market of the London Stock Exchange

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Diaceutics PLC ORD GBP0.002

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Peter Keeling

City and country of registered office (if applicable)

NA

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

12 November 2026

6. Date on which issuer notified:

12 November 2026

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

13.78%

0.33%

14.11%

12,034,517

Position of previous notification (if applicable)

17.88%

0.33%

18.21%

15,534,517

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

8 A: Voting rights attached to shares

Class/type of
shares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Ordinary share of £0.002 (GB00BJQTGV64)

5,626,025

6,126,024

6.60%

7.18%

SUBTOTAL 8. A

11,752,049

13.78%

8 B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expiration
date x

Exercise/
Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

8 B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expiration
date x

Exercise/
Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

Employee share option

17/04/27

17/04/23 to 17/04/27

£1.265 per share

180,000

0.21%

Employee share option

18/05/30

18/05/26 to 18/05/30

£0.002 per share

102,468

0.12%

SUBTOTAL 8.B.2

282,468

0.33%

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

X

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Peter Keeling

6.60%

0.33%

6.93%

Delia Keeling

7.18%

-%

7.18%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

Place of completion

AIM Market of the London Stock Exchange

Date of completion

13 November 2026

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Diaceutics PLC ORD GBP0.002

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Ryan Keeling

City and country of registered office (if applicable)

NA

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

12 November 2026

6. Date on which issuer notified:

12 November 2026

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

2.80%

1.92%

4.72%

4,031,566

Position of previous notification (if applicable)

3.51%

1.92%

5.43%

4,631,566

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

8 A: Voting rights attached to shares

Class/type of
shares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Ordinary share of £0.002 (GB00BJQTGV64)

2,390,643

2.80%

SUBTOTAL 8. A

2,390,643

2.80%

8 B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expiration
date x

Exercise/
Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

8 B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expiration
date x

Exercise/
Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

Employee share option

17/04/27

17/04/23 to 17/04/27

£1.265 per share

180,000

0.21%

Employee share option

18/05/30

18/05/26 to 18/05/30

£0.002 per share

93,407

0.11%

Employee share option

23/07/31

23/07/27 to 23/07/31

£0.002 per share

236,250

0.28%

Employee share option

24/10/29

24/10/24 to 24/10/29

£0.002 per share

557,953

0.65%

Employee share option

22/07/32

22/07/28 to 22/07/2032

£0.002 per share

271,688

0.32%

Employee share option

23/10/33

23/10/29 to 23/10/2033

£0.002 per share

301,625

0.35%

SUBTOTAL 8.B.2

1,640,923

1.92%

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

X

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

Place of completion

AIM Market of the London Stock Exchange

Date of completion

13 November 2026

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

Diaceutics PLC on 6ix

Story so far

Earlier from Diaceutics

All Diaceutics news releases